Ovarian Carcinoma
Conditions
Brief summary
Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many patients with ovarian carcinoma showed resistance to chemotherapy. Cleaved FasL is known for induced atypical response when is binding to Fas such as avoiding apoptosis and inducing cell motility.
Interventions
None listed
Sponsors
Rennes University Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Pre-Inclusion Criteria: \- Patient with suspicious ovarian carcinoma using clinical data, biological data (ca125) and radiological data (CT) Inclusion Criteria: * Pathological ovarian carcinoma diagnosed at pathological analysis after surgery. * Neo adjuvant chemotherapy
Exclusion criteria
* no neo-adjuvant chemotherapy * no ovarian carcinoma at final pathological analysis * less than 18 years old.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between cleaved FasL level ans neoadjuvant chemotherapy tumor response | surgery | Main outcome is cleaved FasL level and correlation with neoadjuvant chemotherapy tumor response, evaluated during surgery. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Identification of tumoral T cells | surgery | Identification of tumoral T cells with FACS analysis of dissociated tumor. Different T cells will be studies: Treg/Th17/Th1/Th2 using antibodies against: CD45/CD3/CD4/CD25/FOXP3 (Treg), CD45/CD3/CD4/IL17A (Th17), CD45/CD3/CD4/CD8/IL4/INF (TCD8 and LTCD4 Th1 et Th2). |
| Disease Free Survival rate | 18 months after surgery | — |
| Overall survival rate | 18 months after surgery | — |
Countries
France
Outcome results
None listed